Background {#Sec1}
==========

The progressive ageing of the population has caused an increase in aortic valve procedures due to degenerative diseases \[[@CR1]\], while mortality has decreased thanks to improvements in surgical techniques \[[@CR2]\]. The current "gold standard" is conventional surgery with a full median sternotomy (FS) to replace the aortic valve. In the last decade, to minimise invasiveness and improve outcomes, there has been an increase in the use of smaller incisions such as the ministernotomy (MS) and new technologies (transcatheter aortic valve implantation (*TAVI*), or sutureless valves).

Minimally invasive aortic valve replacement (AVR) surgery was first described in 1993 \[[@CR3]\] and popularised between 1996 and 1997 \[[@CR4]\] as an alternative to FS for patients with isolated aortic valve or ascending aorta pathologic conditions. Various techniques have been described, although currently the most frequently used is MS (partial upper hemisternotomy extended in a J-shape into the right fourth intercostal space, Fig. [1](#Fig1){ref-type="fig"}) \[[@CR5]\]. In 2008, the American Heart Association defined minimally invasive surgery as "a small chest wall incision that does not include the conventional FS" \[[@CR6]\].Fig. 1Ministernotomy extended in a J-shape into the right fourth intercostal space. **a** Before sawing. **b** Surgical view after sawing, retraction and cannulation

To date, few clinical trials have been conducted that compare AVR surgery using MS versus FS \[[@CR7]--[@CR11]\]. No significant differences have ever been found, due to inadequate design, lack of statistical power or too small a sample size for the primary endpoint of mortality, even though there have been significant differences in morbidity with MS (lower rates of pain, transfusions, bleeding, mechanical ventilation time, stay in intensive care and hospital, etc.) To detect differences in mortality with sufficient power, over 1100 patients would be needed for each branch of the study. This circumstance caused a spate of retrospective studies analysing propensity scores, and meta-analysis \[[@CR12]--[@CR14]\], which confirmed a reduction in postoperative morbidity, and demonstrated a decrease in early \[[@CR13]--[@CR15]\], and even in late, mortality \[[@CR13]\]. But there is an evident bias inherent to retrospective studies. This increased the use of MS worldwide, above all as a result of the spread of TAVIs.

There have been no prospective studies to measure patient quality of life (QOL) and compare the techniques of MS versus FS for AVR. There has only been one retrospective study, with results that are not statistically significant \[[@CR16]\]. Two clinical trials have compared TAVI versus FS (the PARTNER \[[@CR17]\] and the Core Valve PIVOTAL trials \[[@CR18]\]) but they did not analyse MS. QOL has always been relevant to the patient; however, clinicians have not given it enough relevant focus, and it is usually and statistically significant in the first month in favour of TAVI \[[@CR17], [@CR18]\], with all data coming from secondary analysis, not primary endpoints.

Patient-reported QOL outcomes were selected to be the primary endpoint because if similar recovery time and QOL to TAVI is demonstrated, MS provides the capacity of implantation of more durable valves; therefore, it would be used in patients at low and intermediate risk, given the unknown long-term durability of TAVI valves after 5 years. To date, however, there has been no specifically designed QOL study. For all of these reasons, we designed this clinical trial to compare the QOL after MS versus FS. Satisfaction with the surgery and morbimortality outcomes will also be measured.

Methods/design {#Sec2}
==============

This randomised clinical trial follows the standard protocol items: recommendation for interventional trials (SPIRIT) guidelines (see Additional file [1](#MOESM1){ref-type="media"}). The study schedule of enrolment, interventions, and assessments is presented in Fig. [2](#Fig2){ref-type="fig"}.Fig. 2Standard protocol items: recommendation for interventional trials (SPIRIT) figure of participant timeline. EQ5D, Euroqol 5 dimensions Quality of life Questionnaire; M, month; NYHA, New York heart Association; OR, surgery in the operating room; PREOP, preoperative; VAS, visual analogue scale

Study design and endpoints {#Sec3}
--------------------------

This is a pragmatic \[[@CR19]\], independent (not industry supported), single-blind (patient), single centre, randomised clinical trial that compares two treatment groups: patients undergoing AVR with FS or with MS. The study was approved by our Institution's Ethics Committee for Research (Institutional Review Board), and was registered at [ClinicalTrials.gov](http://clinicaltrials.gov) **(NCT02726087**) before the first patient was randomised on 18 March. At January 2018, current protocol version is 1.4 after minor changes were performed.

Quality of life and satisfaction questionnaires {#Sec4}
-----------------------------------------------

The outcome of heart surgery may be evaluated by means of "hard" outcomes, such as mortality, survival, morbidity and heart function, or at different points in time, but the impact of the operation is not merely limited to these biological aspects. An adequate assessment should cover other areas, such as psychological and social aspects, which requires the use of psychometric tools, such as questionnaires. Within these areas, one of the most important is assessment of patient QOL, whereby questionnaires are used to explore physical, psychological and emotional aspects.

There are a multitude of questionnaires including the Short Form 36-item Health Survey \[[@CR20]\], the Minnesota Living with Heart Failure (MLWHF) \[[@CR21]\], the Short Form 12 \[[@CR22]\], the Kansas City Cardiomyopathy Questionnaire (KCCQ) \[[@CR23]\], and the EuroQoL 5 Dimensions 5 Levels (EQ-5D-5 L®) \[[@CR24]\]. We chose the latter as it had been tested in the Spanish population in the Spanish National Health Survey 2011--2012. It was validated for cardiovascular pathologies and it can measure a health unit, the quality-adjusted life year (QALY).

**The EQ-5D-5 L® questionnaire** presents various utilities to measure QOL. The main ones are a descriptive system that can be used to calculate an EQ-index and the visual analogue scale (**VAS**); other utilities may also be calculated such as the severity index or the health index. This questionnaire estimates the state of health in 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression), with five possible responses depending on extent (5 levels: no problems, slight problems, moderate problems, severe problems, unable to /extreme problems). The **EQ-5D-5 L® index** is calculated via the application, the EQ-5D-5 L® Crosswalk Index Value Calculator, using a logistic regression model. Thus, EQ-5D-5 L® (5 dimensions on 5 levels) distinguishes 3125 states of health. The index takes values between 1 (state of health 11111) and − 0.654 (state of health 55555) in the Spanish population.

The subjective state of health is estimated using the VAS of 0 to 100, where 0 is the worst imaginable health and 100 is the best imaginable health.

The **Severity Index (SI)** is obtained by adding the digits that correspond to the levels of the 5 dimensions in each state of health, subtracting 5 and multiplying by 5, which produces a new index (0--100), where 0 indicates a total absence of health problems and 100 is the highest degree of severity. Subtracting the SI from 100 will give the **Health Index (HI).**

As soon as the patient has signed the consent form, the baseline preoperative questionnaires will be completed, which will be repeated at 1, 6 and 12-month follow up. All questionnaires can be completed in person or by telephone interview.

**The SATISCORE® questionnaire** \[[@CR25]\] assesses patient satisfaction after undergoing heart surgery. It analyses six dimensions of satisfaction with the surgery: vitality, sociability, mood, sexuality, self-perception and rest. It consists of twenty statements (Table [1](#Tab1){ref-type="table"}) with 6 possible responses on a Likert scale: 0, no answer; 1, very unsatisfied; 2, unsatisfied; 3, don't know; 4, satisfied; and 5, very satisfied. Scores range from 0 to 100 and it is valid specifically to evaluate the satisfaction of patients who have undergone heart surgery. It is completed at 1 month and 6 months post-surgery.Table 1Items included in the SATISCORE® questionnaireFeeling of illnessPainFeeling of fatigueFeeling when you get up in the morningExercise you have been indicatedPharmacological treatmentFeeling about the operationFeeling of tirednessYour state of healthPerception of future healthAttitude to your illnessThe life you lead todayFeeling about the operationFamily relationshipsFriendshipsMedical assistance received in the hospitalWillingness to repeat the operationFuture plansSex lifePrecaution in sexual relations due to the operation

Selection of patients, randomisation and follow up {#Sec5}
--------------------------------------------------

The study will recruit patients over the age of 18 years, who have severe aortic stenosis or double aortic lesion with predominant stenosis, who are symptomatic according to current guidelines \[[@CR26]\] and also meet the inclusion and exclusion criteria (Table [2](#Tab2){ref-type="table"}). All patients will receive oral and written information from a staff surgeon about the study and then as an informed patient sign a consent form before their inclusion and randomisation in the study. These data were recorded in the hospital computerized healthcare database.Table 2Inclusion and exclusion criteriaInclusion criteria • Severe aortic stenosis (calcified aortic valve, aortic valve area \< 1 cm^2^ or body surface area index \< 0.6 cm^2^, mean transvalvular gradient \> 40 mmHg or peak systolic velocity \> 4 m/s) or double aortic lesion with predominance of stenosis • Sympotomatic (dyspnea NYHA score ≥ 2, angina or syncope) • Age ≥ 18 years • Capacity to give informed consentExclusion criteria • Moderately depressed ejection fraction (\< 40%) • Prior heart surgery (redo operation) • Emergent surgery (within the first 24 h of admission) • Infectious endocarditis • Chronic obstructive pulmonary disease greater than moderate (forced expiratory volume at 1 s (FEV1) predicted \< 60% measured by spirometry) • Need for concomitant surgery except Morrow myectomy preoperative or intraoperative

Randomisation is performed using a randomisation computer programme, in blocks of four patients in a ratio of 1:1. Allocation concealment is achieved by an administrative officer who maintains custody of the randomisation sequence (sequentially numbered), and communicates to medical staff the treatment assigned. This is performed after the consent form has been signed and the surgery scheduled. The patient is blinded with respect to the treatment received. All wounds will be covered up to this moment with standardised wound dressings. There is great difficulty in blinding surgical procedures for a long time, because incisions and scars may differ between groups \[[@CR27]\]. That is why the size of the wounds in both arms will be intended to be as small as possible, about 10 cm in the ministernotomy and 13--15 cm in conventional surgery. A standardized hospital discharge report will be used, without breaking the blinding unless it is strictly necessary due to medical needs, up to the final follow-up assessment at 1 year post-surgery. With these measures we will try to reduce the risk of bias, which will always be present in this type of study involving surgical procedures (for example with a surgeon who is not blinded to procedure). The outcome assessor is the Hospital Clinical Trials Data Monitoring Unit, independent from the Sponsor, which reviews and confirms all the outcomes and endpoint values every 3 months. Both groups of patients will receive clinical follow up and complete the EQ-5D-5 L® quality of life questionnaire at 1, 6 and 12 months, and the SATISCORE® at 1 and 6 months.

Any changes to the research protocol will be reviewed by the Institutional Review Board (IRB). Amendments will be made to the trial registry as necessary.

Study endpoints {#Sec6}
---------------

The primary endpoint measure is to detect differences between MS (active treatment) and FS (control) greater than or equal to 0.10-point change from the baseline questionnaire EQ-5D-5 L® Index, at 1, 6 or 12 months after the surgery.

The secondary endpoint measures are:Differences between intervention groups greater than or equal to 10 point-change from the baseline questionnaire EQ-5D-5 L® utilities such as VAS, SI and HI at 1, 6 or 12 months post-surgery.Early postoperative combined endpoint of four major adverse complications (MAC) at 1 month (safety endpoint), including all-cause mortality, acute myocardial infarction, stroke or transient ischaemic accident, and classification of acute renal failure by Acute Kidney Injury Network (AKIN) greater than or equal to 2. Follow up at 1 year post-surgery.Severe nosocomial infections (pneumonia, early endocarditis, mediastinitis, sepsis).Need for rehospitalisation.Differences between interventions groups greater than or equal to 10 points change from the baseline SATISCORE® questionnaire at 1 and 6 months post-surgery.Postoperative hospital length of stay.Postoperative intensive care unit length of stay.Times for ischaemia and cardiopulmonary bypass (CPB).Mechanical ventilator support after surgery (intubation times).Bleeding in the first 24 h after surgery and transfusion requirements in the first 72 h.New York Heart Association (NYHA) functional class at 1 to 6--12 months.Survival at 12 months.

Sample size calculation {#Sec7}
-----------------------

A review of previous work \[[@CR28], [@CR29]\] shows that the standard deviations of the EQ-5D-5 L® index in cardiovascular disease varies between 0.10 and 0.22, while VAS score varies between 8 and 21 depending on the severity. Likewise, in the only (multicentre) study \[[@CR17]\] that determines quality of life in aortic stenosis, the standard deviation for high-risk patients scheduled for AVR was 0.17 in patients randomised to FS versus TAVI. For these reasons, on summary of all previous work, we used a standard deviation of 0.15 for the EQ-5D-5 L® index to calculate the sample size.

In QOL studies, it is not only important to ascertain whether there are significant differences, but also to know if these differences are clinically relevant. This is why the concept of the **minimal important difference (MID)** was created, which in previous research among patients with cancer was 0.08 points on the EQ-5D index and 7--11 points on the VAS \[[@CR29]\], and in patients with stroke it was 0.10 points on the EQ-index (95% CI 0.08--0.12) \[[@CR28]\]. This difference was also 0.06 points (95% CI 0.02--0.10) on the EQ index during the first month in the PARTNER 1 study (transfemoral TAVI versus FS) \[[@CR17]\], and 0.12 (95% CI 0.08--0.16) in the CoreValve PIVOTAL trial study \[[@CR18]\]. As there was no existing specific calculation of MID for cardiology patients with severe aortic stenosis, we arbitrarily established the interval of 0.10 points on the EQ-5D index (the mean value from previous studies) as the clinically relevant difference to detect. Thus, to detect an MID of at least 0.10 points in the QOL scale EQ-5D-5 L® index, with alpha error of 0.05, beta error of 0.1 and power of 90% for two-tailed contrast of two independent means (SD 0.15), two groups of 48 patients are necessary to provide a minimum of 96 patients. In view of possible losses to follow up, 100 patients will be randomised. If patients drop out or are excluded during the study, additional patients will be recruited until a minimum of 96 patients is achieved, and inclusion of an additional patient will be considered again for each patient not completing the 1-year follow-up assessment.

Description of the surgical procedures {#Sec8}
--------------------------------------

### Conventional full median sternotomy {#Sec9}

The patient is positioned supine (dorsal decubitus). The skin is incised from the suprasternal notch to the xiphoid process. Conventional median sternotomy is performed from the manubrium to the xiphoid. The ascending aorta and right atrium are cannulated centrally to initiate CPB. A vent cannula for the left-sided cavities is placed in the right superior pulmonary vein, followed by aortic cross-clamping. Intermittent cold antegrade blood cardioplegia via the root or coronary ostia every 20 min, transverse aortotomy, valve extraction and decalcification of the annulus are performed. AVR is performed using Ti-Cron 2/0® polyester suture stitches supported by Teflon in an aortic ring. The aortotomy is closed using polypropylene monofilament 4/0, followed by aortic unclamping, decannulation and placement of a transitional pacemaker placement. Placement of two sub -xiphoid Blake type drains. Sternal closure with stainless steel wires. The skin incision is closed with a subcutaneous double layer and staples or intradermic suture.

### Ministernotomy {#Sec10}

The patient is positioned supine (dorsal decubitus) and defibrillator external paddles are positioned. An 8 to 10-cm opening is made in the skin starting at the sternal angle. Ministernotomy is defined as a partial upper hemisternotomy extended into a J-shape into the right fourth intercostal space irrespective of the skin incision (usually 8--12 cm in length, Fig. [1](#Fig1){ref-type="fig"}). A 21-mm silicon Blake-type drain is inserted sub-xiphoid. CO2 is administered via the sub-xiphoid drain placed before the CPB was established. The rest of the procedure is similar to that used for FS.

Independent variables in the study. Complications {#Sec11}
-------------------------------------------------

Data on preoperative baseline demographic variables will be recorded in both intervention groups. Most of the definitions of postoperative complications are to be found in the consensus document, *Valve Academic Research Consortium 2* (VARC2) \[[@CR30]\] that arose as a consequence of the generalisation of TAVI, and the need for consistency of definitions and improved comparability of articles. The AKIN classification was used in the VARC 2 criteria according to the European Society of Cardiology (ESC)/European Association for Cardio-Thoracic Surgery (EACTS) recommendations, and it is the only way to compare new data with previous reports/trials of TAVI \[[@CR30]\].

Statistical analysis {#Sec12}
--------------------

Statistical analysis will be performed using IBM SPSS 22.0® for Windows®. First, a descriptive analysis of the study variables will be conducted; the values of quantitative variables will be expressed as mean ± standard deviation (SD) or median (interquartile range) depending on whether distribution of the variable is symmetrical and normal. Qualitative variables will be presented in absolute frequencies and relative frequencies. To analyse the differences between continuous quantitative variables (values of the EQ-5D-5 L® and SATISCORE questionnaires) in the two independent groups (MS vs. FS), Student's *t* test for two independent samples will be applied in cases where the normality of distribution of the variable data in each of the groups can be accepted, which will be checked using the Kolmogorov-Smirnov test, then histograms and Q-Q plots. In cases where normality cannot be accepted, the corresponding non-parametric Wilcoxon test will be applied. In cases where the normality condition can be accepted, Student's *t* test for two-tailed samples will be applied to analyse differences between continuous quantitative variables in two associated groups (QOL data) before and after surgery.

We will apply analysis of variance (ANOVA) for repeated measures to analyse the variability, with repeated measurements over time, of certain continuous quantitative determinations of the questionnaires used. The normality of the remainder will be checked using the Shapiro-Wilk test. In the case of statistically significant differences in the contrasted variables measured at different times, the different levels of time will be checked, adjusting the outcomes using the Bonferroni correction.

To analyse if there are differences between qualitative variables, 2 × 2 tables will be prepared and analysed using the Chi-squared (*X*2) statistical test. This analysis will be performed to evaluate the differences in complications and major adverse events of dichotomous variables. The relative risk ratio and the corresponding confidence intervals will be calculated to 95% for the MS versus FS technique as a combined safety endpoint of MAC complications.

Multivariate regression analysis techniques will be applied to control possible bias in effect caused by the patient's initial situation (comorbidities). Pearson's correlation test will be performed on EQ-5D-5 L® and SATISCORE® data. Survival analysis will be conducted using Mantel Cox log-rank analysis with the corresponding Kaplan-Meier survival chart.

The "intention to treat" population is defined to include all randomised subjects. This population will be used for endpoint analyses. The as-treated population ("per protocol") is defined to include all subjects undergoing the index procedure. This population will be used for the analysis of adverse events.

Differences between MS and FS group scores at each follow-up time point will be estimated with longitudinal random-effect growth curve models, which will be fit to the repeated measurements for each health status outcome. These longitudinal analyses will use all available quality-of-life data: including data from patients who will subsequently die, withdr~~a~~w, or will be lost to follow up. They will also accommodate missing data under the missing at random assumption. Variables that will be included in the models are: treatment assignment, pre-specified patient characteristics (age, sex, EuroScore), follow-up time and interactions between treatment and time. These models will be used to calculate the mean between-group differences in the EQ-5D index score and the individual subscales at each follow-up time point, and the associated 95% CIs and *P* values.

To examine the potential impact of missing data, which, given the illness severity of the trial population, would most likely not be missing at random, we will repeat the growth curve analyses after imputing the missing scores among the surviving patients, as the lowest reported score among respondents within each treatment group for each respective time point. We also will examine the magnitude of potential survivor bias by comparing the mean baseline scores between treatment groups for the subgroups of patients with available QOL data at each successive follow-up time point.

Dissemination {#Sec13}
-------------

Trial results will be posted on [ClinicalTrials.gov](http://clinicaltrials.gov), published in peer-reviewed journals, and presented at national conferences. Data-sharing policy will be under request to the Sponsor and publicly explained and recorded at [ClinicalTrials.gov](http://clinicaltrials.gov).

Limitations of the study {#Sec14}
------------------------

Among this study's limitations, there could be some confusion bias introduced by variables, which will be controlled in the statistical analysis using multivariate linear regression analysis. The absence of masking the surgeon may introduce an unmeasurable bias into the study. The sample size is not designed to detect differences in mortality, although a combined safety endpoint such as this one may help to find differences between groups. The use of general QOL questionnaires such as EQ-5D-5 L means that the outcome does not depend exclusively on the surgical technique employed, but also on other diseases and/or complaints that the patient has previously or that may be acquired in the future, independently of the heart condition. The size of the sample could also be insufficient if the standard deviations are shown to be higher than those presented in previous research.

Summary and trial status {#Sec15}
========================

The QUALITY-AVR trial (NCT02726087) aims to test the hypothesis that MS improves QOL, satisfaction and clinical outcomes in patients referred for isolated AVR. The design of this study is unique to date, as there is no randomised clinical trial to have compared these outcomes. We hope that the results of the study can influence the future of AVR surgery and encourage the adoption of a new surgical "gold standard" for MS, with improved QOL and outcomes, in the short and long term. If this proves to be the case, clinical trials comparing TAVI to surgery should include MS to evaluate outcomes in low and intermediate risk patients as the "control" group. Recruitment began in March 2016 (75 patients currently recruited at November 2017) and it is expected to end in May 2018. All outcomes will be published within 2 years in accordance with Consolidated Standards on Reporting Trials (CONSORT) recommendations.

Additional file
===============

 {#Sec16}

Additional file 1:SPIRIT 2013 checklist: Recommended items to address in a clinical trial protocol and related documents. (DOCX 52 kb)

AKIN

:   Acute Kidney Injury Network

AVR

:   Aortic valve replacement

CBP

:   Cardiopulmonary bypass

EQ-5D-5 L

:   EuroQOL Quality of life Questionnaire 5 dimensions 5 Levels

FS

:   Full sternotomy (conventional surgery)

HI

:   Health Index

MAC

:   Major adverse complications

MS

:   Mini sternotomy

QOL

:   Quality of life

SI

:   Severity Index

*TAVI*

:   Transcatheter aortic valve implantation

VAS

:   Visual analogue scale
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